arrow
P

Philipp B. Staber

Medical University of Vienna
H指数:37
被引数:5,316

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Preclinical models of hepatosplenic γδ T-cell lymphoma with an activating STAT5B mutation display sensitivity to JAK inhibitor upadacitinib

具有激活STAT5B突变的肝脾 γ δ T细胞淋巴瘤的临床前模型对JAK抑制剂upadacitinib敏感

2026-04-160
OAAI
Time-limited venetoclax combinations in untreated chronic lymphocytic leukemia: Five-year results and patient-reported outcome analysis of the randomized phase 3 CLL13/GAIA trial

限时Venetoclax联合疗法在初治慢性淋巴细胞白血病中的应用:CLL13/GAIA随机III期试验的五年结果及患者报告结局分析

Blood
IF23.1
2026-04-010
PRE
Single-cell genomics highlight MYC-associated metabolic activation and altered cell interactions in T-prolymphocytic leukemia progression

单细胞基因组学揭示了MYC相关的代谢激活以及在T原淋巴细胞白血病进展中改变的细胞相互作用

2026-03-090
OAAI
Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma

通过MYC抑制miR-29会导致转化性滤泡性淋巴瘤中CD40信号增强

Leukemia
IF13.4
2026-02-190
OA
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

Al-Sawaf, O.; Stumpf, J.; Zhang, C.; Simon, F.; Bosch, F.; Feyzi, E.; Ghia, P.; Gregor, M.; Kater, A.P.; Lindström, V.; 等. 固定疗程与持续治疗在慢性淋巴细胞白血病中的应用比较. N. Engl. J. Med. 2025, 393, 24. [Google Scholar] [CrossRef]

2025-12-018
PRE
Changes in cardiac parameters during venetoclax treatment

在venetoclax治疗期间的心脏参数变化

2025-10-010
OAAI
Comparing functional and genomic-based precision medicine in blood cancer patients

比较基于功能与基因组学的血液肿瘤患者精准医学

2025-04-240
OAAI
Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia

过度活跃的STAT5劫持T细胞受体信号并驱动未成熟的T细胞急性淋巴细胞白血病

2024-04-151
OAAI
Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

淋巴细胞耗竭-嵌合抗原受体T细胞治疗周期的重要但被低估的部分

2023-12-2229
OAAI
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
2023-12-0914
OAAI
The impact of COVID-19 and socioeconomic status on psychological distress in cancer patients
2023-10-012
OAAI
CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS
LEUKEMIA
IF13.4
2023-09-060
OA